Published in HIV Med on December 28, 2009
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis (2002) 1.90
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS (2001) 1.60
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther (2003) 1.55
Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS (1997) 1.30
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS (2000) 1.01
Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA (1999) 1.01
Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur J Med Res (2000) 0.94
CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis (1999) 0.93
CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS (2000) 0.91
Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. HIV Med (2007) 0.89
CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS (2001) 0.87
Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med (2004) 0.82
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet (1999) 6.40
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA (2001) 3.28
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Staphylococcus lugdunensis endocarditis. Lancet (1989) 3.21
Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol (1987) 3.01
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. Arch Intern Med (1993) 2.57
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med (1993) 2.55
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med (2008) 2.43
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group. AIDS (1997) 2.21
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.87
Procedures associated with infective endocarditis in adults. A case control study. Eur Heart J (1995) 1.84
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis (2000) 1.78
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS (1999) 1.75
Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer (2006) 1.73
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials (2001) 1.71
Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin Infect Dis (1995) 1.70
Pyogenic and tuberculous spondylodiskitis (vertebral osteomyelitis) in 80 adult patients. Clin Infect Dis (1994) 1.69
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol (2001) 1.68
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis (1998) 1.67
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 1.63
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol (2000) 1.62
Characteristics of infective endocarditis in France in 1991. A 1-year survey. Eur Heart J (1995) 1.57
Allelic repertoire of the human MHC class I MICA gene. Immunogenetics (1996) 1.57
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology (1993) 1.56
Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am J Med (2000) 1.56
Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. Br J Dermatol (2012) 1.56
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Saline spa water or combined water and UV-B for psoriasis vs conventional UV-B: lessons from the Salies de Béarn randomized study. Arch Dermatol (2001) 1.53
The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr (2001) 1.51
Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics (2000) 1.51
Clinical and bacterial features of infections caused by Streptococcus milleri. Scand J Infect Dis (1991) 1.51
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group. J Infect Dis (1995) 1.51
Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis (1998) 1.50
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res (2012) 1.48
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother (2008) 1.47
Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis (1998) 1.44
Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med (2002) 1.44
Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol (1996) 1.43
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis (1995) 1.43
The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy (2004) 1.42
Antibiotic prophylaxis of late bacteremic vascular graft infection in a dog model. Ann Vasc Surg (1990) 1.41
Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med (2007) 1.40
[Zona in 50 patients infected by human immunodeficiency virus. Clinical manifestations and prognostic value]. Presse Med (1990) 1.40
[Varicella zoster virus infection area in 39 HIV-infected patients. Therapeutic management]. Presse Med (1999) 1.40
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups. J Immunol (2000) 1.39
[Cerebral toxoplasmosis concomitant with primary toxoplasma infection in AIDS]. Presse Med (1992) 1.39
A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis (1996) 1.39
Detection of microsporidia and identification of Enterocytozoon bieneusi in surface water by filtration followed by specific PCR. J Eukaryot Microbiol (1998) 1.38
Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood (1999) 1.36
Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med (2007) 1.36
Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol (2001) 1.35
Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol (1989) 1.35
Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol (1990) 1.35
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol (1989) 1.33
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med (2005) 1.32
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother (2011) 1.32
Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med (1999) 1.30
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol (2009) 1.30
Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS (1997) 1.30
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29
Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol (1990) 1.28
Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology (1991) 1.28